Overall, PTβR2I appeared to inhibit the TGFβ1/p-Smad2/3 pathway under normal glucose conditions while having no substantial inhibition effect when the glucose level was as high as that found in diabetes. The gene discussed is SMAD2; the disease is diabetes mellitus.